PEPTONIC MEDICAL (28L) - Total Liabilities
Based on the latest financial reports, PEPTONIC MEDICAL (28L) has total liabilities worth €27.67 Million EUR (≈ $32.35 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PEPTONIC MEDICAL operating cash flow efficiency to assess how effectively this company generates cash.
PEPTONIC MEDICAL - Total Liabilities Trend (2021–2025)
This chart illustrates how PEPTONIC MEDICAL's total liabilities have evolved over time, based on quarterly financial data. See PEPTONIC MEDICAL book value and equity for net asset value and shareholders' equity analysis.
PEPTONIC MEDICAL Competitors by Total Liabilities
The table below lists competitors of PEPTONIC MEDICAL ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Marshalls PLC
LSE:MSLH
|
UK | GBX430.70 Million |
|
GGL Resources Corp
V:GGL
|
Canada | CA$35.30K |
|
Aeeris Ltd
AU:AER
|
Australia | AU$891.79K |
|
Randgold Exploration
JSE:RNG
|
South Africa | ZAC10.99 Million |
|
Onfolio Holdings Inc
NASDAQ:ONFO
|
USA | $7.46 Trillion |
|
Click Holdings Limited
NASDAQ:CLIK
|
USA | $20.04 Million |
|
Halo Technologies Holdings Ltd
AU:HAL
|
Australia | AU$408.41 Million |
|
GLOW LIFETECH CORP.
F:9DO
|
Germany | €1.48 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down PEPTONIC MEDICAL's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PEPTONIC MEDICAL (28L) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.72 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PEPTONIC MEDICAL's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PEPTONIC MEDICAL (2021–2025)
The table below shows the annual total liabilities of PEPTONIC MEDICAL from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €27.67 Million ≈ $32.35 Million |
+25.72% |
| 2024-12-31 | €22.01 Million ≈ $25.73 Million |
-29.94% |
| 2023-12-31 | €31.41 Million ≈ $36.73 Million |
-18.75% |
| 2022-12-31 | €38.66 Million ≈ $45.20 Million |
+22.80% |
| 2021-12-31 | €31.48 Million ≈ $36.81 Million |
-- |
About PEPTONIC MEDICAL
PEPTONIC medical AB (publ), a medical technology company, develops and sells intimate self-care products for women. The company offers products under the VagiVital brand, including a moisturizing gel for atrophy; an intimate calming gel for rapid relief of itching and irritation; moisturizing lubricant; a pH-balancing intimate wash/conditioner; self-test kits for diagnosing pre-menopause, menopau… Read more